

FIGURE 8.17

Bioactivation of psammaplin A and interaction of the active thiol with HDAC1.



8.18 **8.19**

3.6 INHIBITORS OF HDAC4

The histone deacetylase HDAC4 could be a useful target for new anticancer therapies because its inhibition induces *p21WAF1/Cip1* gene expression and arrests cancer cell growth.[72] Tasquinimod is an allosteric modulator of this enzyme that inhibits HDAC4 client transcription factors bound at promoter/enhancers where epigenetic reprogramming is required for cancer cell survival and angiogenic response. It is an orally active antiangiogenic drug that is currently in phase III clinical trials for the